Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Futura Medical ( (GB:FUM) ) has shared an announcement.
Futura Medical announced a board change as Harmesh Suniara steps down as Non-Executive Director following a reduction in Lombard Odier Asset Management’s shareholding. This change comes after a successful fundraising, which provides the company with a stable financial footing. Futura is now focused on completing a strategic review and advancing the development of its products, Eroxon Intense and WSD4000, which could significantly impact the sexual health market.
The most recent analyst rating on (GB:FUM) stock is a Buy with a £140.00 price target. To see the full list of analyst forecasts on Futura Medical stock, see the GB:FUM Stock Forecast page.
More about Futura Medical
Futura Medical plc is a consumer healthcare company specializing in the development and global commercialization of innovative and clinically proven sexual health products. Their core strength lies in research, development, and commercialization of topically delivered gel formulations, with products like Eroxon® for erectile dysfunction and WSD4000 for impaired sexual response in women. The company has established distribution partnerships in major markets, including the US and Europe.
Average Trading Volume: 2,956,141
Technical Sentiment Signal: Sell
Current Market Cap: £3.7M
Learn more about FUM stock on TipRanks’ Stock Analysis page.